Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo

Pandemic Flu and Medical Biodefense Countermeasure Liability Limitation (CRS Report for Congress)

Premium   Purchase PDF for $24.95 (8 pages)
add to cart or subscribe for unlimited access
Release Date Revised Feb. 12, 2010
Report Number RS22327
Report Type Report
Authors Henry Cohen and Vanessa Burrows, American Law Division
Source Agency Congressional Research Service
Older Revisions
  • Premium   Revised Feb. 10, 2010 (8 pages, $24.95) add
  • Premium   Revised Jan. 15, 2008 (8 pages, $24.95) add
  • Premium   Revised April 5, 2007 (6 pages, $24.95) add
  • Premium   Revised Dec. 5, 2006 (6 pages, $24.95) add
  • Premium   Revised April 12, 2006 (6 pages, $24.95) add
  • Premium   Revised Dec. 20, 2005 (6 pages, $24.95) add
  • Premium   Nov. 18, 2005 (4 pages, $24.95) add
Summary:

Division C of P.L. 109-148 (2005), 42 U.S.C. §§ 247d-6d, 247d-6e, also known as the Public Readiness and Emergency Preparedness Act (PREP Act), limits liability with respect to pandemic flu and other public health countermeasures. Specifically, upon a declaration by the Secretary of Health and Human Services of a public health emergency or the credible risk of such emergency, Division C would, with respect to a "covered countermeasure," eliminate liability, with one exception, for the United States, and for manufacturers, distributors, program planners, persons who prescribe, administer or dispense the countermeasure, and employees of any of the above. The exception to immunity from liability is that a defendant who engaged in willful misconduct would be subject to liability under a new federal cause of action, though not under state tort law, if death or serious injury results. Division C's limitation on liability is a more extensive restriction on victims' ability to recover than exists in most federal tort reform statutes. However, victims could, in lieu of suing, accept payment under a new "Covered Countermeasure Process Fund," if Congress appropriates money for this fund. The first PREP Act declaration was issued on January 26, 2007, to limit liability for the administration of the H5N1 influenza vaccine. Since then, declarations have been issued covering countermeasures against other strains of influenza (including H1N1), anthrax, botulism, small pox, and acute radiation syndrome.